Recruiting NA ACL Injury

New treatment option for ACL Injury

Official title Augmentation of Partial Anterior Cruciate Ligament Tear: Early Results

ClinicalTrials.gov ID: NCT05391672

What this study is testing

What it's testing
Clinical evaluation for the patients with partial ACL tear who had ACL augmentation

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 15 to 50

You may be able to join if

  • age from 15 to 50 years old
  • Partial ACL tear without any other ligament injury
  • with and without meniscal tear
  • with and without knee deformity
  • recent and chronic injury

You likely can't join if

  • younger than 15 and older than 50 y
  • multiligament injury
  • complete ACL tear
  • failed ACL reconstruction or repair

The study team makes the final eligibility decision.

Where it's taking place

  • Asyut, Egypt

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 15 years to 50 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Asyut, Egypt. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.